[1] Deng SQ, Peng HJ.Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China[J]. J Clin Med, 2020, 9(2): 575. [2] Chinese Center for Disease Control and Prevention. Distribution of novel coronavirus pneumonia[EB/OL]. (2020-08-27)[2020-08-28]. http://2019ncov. chinacdc. cn/2019-nCoV/global. html. [3] General Office of National Health Commission, Office of National Administration of Traditional Chinese Medicine. Notice on issuing the new coronavirus pneumonia diagnosis and treatment plan (Trial Version 6) (Guoweiban Yihan [2020] No. 145) [EB/OL]. (2020-02-18)[2020-04-18]. http://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2. shtml. [4] Jia HP, Song Q, Wang L, et al.Anti-coronavirus effect and safety research progress of chloroquine[J]. Chin J Pharm Toxicol(中国药理学与毒理学杂志), 2020, 34(4): 272-277. [5] Vincent MJ, Bergeron E, Benjannet S, et al.Chloroquine is a potent inhibitor of SARS coronavirus infection and spread[J]. Virol J, 2005, 2:69. [6] Zumla A, Chan JF, Azhar EI, et al.Coronaviruses - drug discovery and therapeutic options[J]. Nat Rev Drug Discov, 2016, 15(5): 327-347. [7] Wilde AH, Jochmans D, Posthuma CC, et al.Screening of an FDA-approved compound library identifies four small-molecule inhibitors of middle east respiratory syndrome coronavirus replication in cell culture[J]. Antimicrob Agents Chemother, 2014, 58(8): 4875-4884. [8] Rosenberg ES, Dufort EM, Udo T, et al.Association of treatment with hydroxychloroquine or zithromycin with in-hospital mortality in patients with COVID-19 in New York State[J/OL]. JAMA, 2020: 323(24): 2493-2502. [9] Tang W, Cao Z, Han M, et al.Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial[J]. BMJ, 2020, 369: m1849. [10] FDA. Coronavirus (COVID-19) update: FDA revokes emergency use authorization for chloroquine and hydroxychloroquine[EB/OL]. (2020-06-15)[2020-06-20]. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and. [11] WHO. Coronavirus disease (COVID-19) situation report - 151[EB/OL]. (2020-06-19)[2020-06-20]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. [12] FDA. FDA adverse event reporting system (FAERS) quarterly data extract files[EB/OL]. (2020-01-15)[2020-05-10]. https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS. html. [13] Canada Vigilance. Data extracts from the Canada vigilance adverse reaction online database[EB/OL]. (2020-04-13)[2020-05-10]. https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-database/canada-vigilance-online-database-data-extract. html. [14] Hou Y, Ye X, Wu G, et al.A comparison of disproportionality analysis methods in national adverse drug reaction databases of China[J]. Expert Opin Drug Saf, 2014, 13(7): 853-857. [15] Noren GN, Bate A, Orre R, et al.Extending the methods used to screen the who drug safety database towards analysis of complex associations and improved accuracy for rare events[J]. Stat Med, 2006, 25(21): 3740-3757. [16] Guo XJ.Study of exact unconditional test based on false discovery rate for signal detection of adverse drug action [D]. Shanghai: The Second Military Medical University, 2015. [17] Li G, Fan Y, Lai Y, et al.Coronavirus infections and immune responses[J]. J Med Virol, 2020, 92(4): 424-432. [18] Pedersen SF, Ho YC.SARS-CoV-2: a storm is raging[J]. J Clin Invest, 2020, 130(5): 2202-2205. [19] Perricone C, Triggianese P, Bartoloni E, et al.The anti-viral facet of anti-rheumatic drugs: Lessons from COVID-19[J]. J Autoimmun, 2020, 111: 102468. [20] Hu TY, Frieman M, Wolfram J.Insights from nanomedicine into chloroquine efficacy against COVID-19[J]. Nat Nanotechnol, 2020, 15(4): 247-249. [21] Gao J, Tian Z, Yang X.Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies[J]. Biosci Trends, 2020, 14(1): 72-73. [22] Huang M, Tang T, Pang P, et al.Treating COVID-19 with chloroquine[J]. J Mol Cell Biol, 2020, 12(4): 322-325. [23] Huang MX, Li M, Xiao F, et al.Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19[J/OL]. Natl Sci Rev, 2020(9):1428-1436. [24] Geleris J, Sun Y, Platt J, et al.Observational study of hydroxychloroquine in hospitalized patients with COVID-19[J]. N Engl J Med, 2020, 382(25): 2411-2418. [25] Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized arial of hydroxychloroquine as postexposure prophylaxis for COVID-19 [J/OL]. N Engl J Med, 2020, 383(6). [2020-06-20]. Doi: 10. 1056/NEJMoa2016638. [26] Sarayani A, Cicali B, Henriksen CH, et al. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine[J/OL]. Res Social Adm Pharm, 2020,17(2). [2020-05-23]. Doi: 10. 1016/j.sapharm. 2020. 04. 016. [27] Touret F, de Lamballerie X. Of chloroquine and COVID-19[J]. Antiviral Res, 2020, 177: 104762. |